- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Anaplastic thyroid cancer.
Displaying page 1 of 2.
| EudraCT Number: 2007-005090-65 | Sponsor Protocol Number: VALPAX | Start Date*: 2007-10-18 | |||||||||||
| Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
| Full Title: New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours | |||||||||||||
| Medical condition: Patients with anaplastic thyroid cancer or with metastatic solid tumours | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-005221-11 | Sponsor Protocol Number: MUTAVA | Start Date*: 2008-10-22 | |||||||||||
| Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
| Full Title: New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel. | |||||||||||||
| Medical condition: Patients with undifferentiated thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004570-34 | Sponsor Protocol Number: 01045-ATLEP | Start Date*: 2018-11-15 | ||||||||||||||||
| Sponsor Name:Medical Center - University of Freiburg | ||||||||||||||||||
| Full Title: Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvat... | ||||||||||||||||||
| Medical condition: Anaplastic (ATC) or Poorly Differentiated Thyroid Carcinoma (PDTC) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2007-002846-38 | Sponsor Protocol Number: OXC4T4-302 | Start Date*: 2007-12-06 | |||||||||||
| Sponsor Name:OXiGENE, Inc. | |||||||||||||
| Full Title: A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with pacli... | |||||||||||||
| Medical condition: Anaplastic Thyroid Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) IT (Completed) BG (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-001032-12 | Sponsor Protocol Number: PANTHERA | Start Date*: 2008-10-28 | |||||||||||||||||||||
| Sponsor Name:Universitätsklinikum Schleswig-Holstein | |||||||||||||||||||||||
| Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
| Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Prohibited by CA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-001066-42 | Sponsor Protocol Number: GETNE-T1812 | Start Date*: 2020-02-20 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-001929-17 | Sponsor Protocol Number: E7080-M000-213 | Start Date*: 2017-01-18 | |||||||||||
| Sponsor Name:EISAI LIMITED | |||||||||||||
| Full Title: This is an Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC). | |||||||||||||
| Medical condition: Anaplastic Thyroid Cancer (ATC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-001618-42 | Sponsor Protocol Number: 20040273 | Start Date*: 2005-07-28 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A Phase 2 Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer | |||||||||||||
| Medical condition: Locally advanced or metastatic thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) HU (Completed) DK (Completed) BE (Completed) AT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001908-17 | Sponsor Protocol Number: 2021.40 | Start Date*: 2022-09-05 | |||||||||||
| Sponsor Name:Leiden University Medical Center | |||||||||||||
| Full Title: Neo- and adjuvant targeted therapy in BRAF-mutated anaplastic cancer of the thyroid (NEO-ATACT study) | |||||||||||||
| Medical condition: BRAF-mutated anaplastic thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-001890-27 | Sponsor Protocol Number: D4200C00079 | Start Date*: 2007-06-15 | |||||||||||
| Sponsor Name:AstraZeneca SAS | |||||||||||||
| Full Title: A Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with advanced or metastatic papillary or follicular Thyroid Car... | |||||||||||||
| Medical condition: Advanced or metastatic papillary or follicular Thyroid Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) DK (Completed) SE (Completed) ES (Ongoing) BE (Completed) PT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003028-59 | Sponsor Protocol Number: NL62684.091.17 | Start Date*: 2018-06-06 |
| Sponsor Name:Radboud University Medical Centre | ||
| Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study | ||
| Medical condition: Anaplastic Thyroid Carcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002243-42 | Sponsor Protocol Number: GCT1021-01 | Start Date*: 2016-10-25 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Genmab A/S | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-016669-27 | Sponsor Protocol Number: P10- | Start Date*: 2010-04-14 |
| Sponsor Name:Leiden University Medical Center | ||
| Full Title: A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyr... | ||
| Medical condition: Patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma will be treated in a phase II study to investigate the efficacy of R... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-001783-75 | Sponsor Protocol Number: SATCG-4 | Start Date*: 2008-03-31 |
| Sponsor Name:Department of Oncology, Lund University Hospital | ||
| Full Title: Phase 2 trial with Avastin and Doxorubicin postoperatively for patients with anaplastic thyroid carcinoma | ||
| Medical condition: Patients that suffer from anaplastic thyroid cancer and have completed our "standard" initial therapy with radiotherapy and chemotherapy, and has been macroscopical radically resected after complet... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-004163-12 | Sponsor Protocol Number: 2020-012-GLOB1 | Start Date*: 2021-11-04 | |||||||||||||||||||||||||||||||
| Sponsor Name:Hutchison MediPharma Limited | |||||||||||||||||||||||||||||||||
| Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-012007-25 | Sponsor Protocol Number: BAY43-9006/14295 | Start Date*: 2009-10-21 | |||||||||||||||||||||
| Sponsor Name:Bayer AG | |||||||||||||||||||||||
| Full Title: A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | |||||||||||||||||||||||
| Medical condition: Differentiated thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) BE (Completed) AT (Completed) SK (Completed) BG (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-000885-13 | Sponsor Protocol Number: UC-0105/1303 | Start Date*: 2013-07-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-005219-16 | Sponsor Protocol Number: GE-135-003 | Start Date*: 2010-12-06 |
| Sponsor Name:GE Healthcare Ltd | ||
| Full Title: A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging | ||
| Medical condition: Adult subjects with Primary or metastatic tumour lesion of one of the following types: high-grade glioma, including GBM, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, inclu... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-000461-23 | Sponsor Protocol Number: CA209-627 | Start Date*: 2017-03-07 | ||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
| Full Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies | ||||||||||||||||||
| Medical condition: Advanced/Metastatic malignancies | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-002260-14 | Sponsor Protocol Number: UC-0105/1612 | Start Date*: 2017-04-03 |
| Sponsor Name:UNICANCER | ||
| Full Title: Secured access to pembrolizumab for adult patients with selected rare cancer types. | ||
| Medical condition: Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare t... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
